SCYNEXIS, Inc. (SCYX): Price and Financial Metrics


SCYNEXIS, Inc. (SCYX)

Today's Latest Price: $6.34 USD

0.14 (2.26%)

Updated Dec 4 4:00pm

Add SCYX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SCYX Stock Summary

  • With a price/sales ratio of 1,257.42, Scynexis Inc has a higher such ratio than 99.47% of stocks in our set.
  • Revenue growth over the past 12 months for Scynexis Inc comes in at -77.73%, a number that bests only 1.83% of the US stocks we're tracking.
  • The volatility of Scynexis Inc's share price is greater than that of 99.5% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Scynexis Inc, a group of peers worth examining would be GERN, CBMG, INO, MRSN, and ADAP.
  • Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.

SCYX Stock Price Chart Interactive Chart >

Price chart for SCYX

SCYX Price/Volume Stats

Current price $6.34 52-week high $12.10
Prev. close $6.20 52-week low $4.20
Day low $6.25 Volume 56,800
Day high $6.44 Avg. volume 97,064
50-day MA $5.29 Dividend yield N/A
200-day MA $6.95 Market Cap 69.36M

SCYNEXIS, Inc. (SCYX) Company Bio


SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.


SCYX Latest News Stream


Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream


Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about Scynexis Inc that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis

* Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.JERSEY CITY, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections, today announced the successful completion of pre-NDA meetings with U.S. Food and Drug Administration (FDA) regarding ibrexafungerp for the treatment of VVC, a common fungal infection that affects millions of women in the U.S. every year.The purpose of the meetings was to discuss and confirm the clinical, non-clinical and chemistry, manufacturing and controls (CMC) conte...

Yahoo | July 29, 2020

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shift From Loss To Profit

SCYNEXIS, Inc.'s (NASDAQ:SCYX): SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal...

Yahoo | July 22, 2020

SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infectionsJERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of four posters at the American Society for Microbiology (ASM) Microbe 2020 held virtually from June through August. The posters, presented as part of the ASM Microbe Online 2020 Summer of Science program, now available online, highlight the potential clinical utility of ibrexafungerp. Ibrexafungerp is the first representative of a new class of antifungal agents called triterpenoids...

Yahoo | July 22, 2020

SCYNEXIS Announces One-for-Ten Reverse Stock Split

JERSEY CITY, N.J., July 16, 2020 -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of.

Yahoo | July 16, 2020

SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections

Discussion will be conducted via Webcast Call on Tuesday, July 14th at 10am Eastern Time Event will highlight the impact of vaginal yeast infections on women, the.

Yahoo | July 9, 2020

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo 41.52%
3-mo 28.34%
6-mo -26.54%
1-year -35.14%
3-year -70.23%
5-year -90.93%
YTD -30.33%
2019 89.58%
2018 -79.31%
2017 -27.27%
2016 -48.63%
2015 -37.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8571 seconds.